Taken from https://anthraxvaccine.blogspot.com/2022/03/the-bmj-editor-in-chief-fiona-godlee.html

This is amazing.  BMJ Editor Godlee knew in August 2020, when the phase 3 vaccine trials were just getting started, that the vaccines:

a) would not be very effective

b) would likely just decrease severity of illness and not prevent infection

c) might become a suboptimal, chronic treatment, and 

d) might change the definition of what we consider a vaccine to be 

How did she know this?  I imagine she knew it from a whistleblower or two or ten.  The public certainly didn't know it.  If she knew it Fauci knew it, along with his Corona Task Force of useful idiots.

Update March 8:  Peter Hotez also knew, in November 2020, the vaccine would not prevent spread and would only reduce severity:

Why didn’t the people know this????  Who sent them the memo???

https://www.medpagetoday.com/infectiousdisease/covid19/89512

"Peter Hotez, MD, PhD, of Baylor College of Medicine in Houston, observed that for the next few months, producing vaccines for the American population will be problematic, so it won't be an issue in this country for a while.

"Even as the first vaccines become more widely available they may be only partially protective to reduce severity of illness and won't stop transmission anyway so we won't need to pay people for that purpose," he told MedPage Today. "So I don't foresee a reason to pay anyone to get vaccinated against COVID-19."'

https://www.bmj.com/content/370/bmj.m3258

Editor's Choice

Covid-19: Less haste, more safety

BMJ 2020; 370 doi: https://doi.org/10.1136/bmj.m3258 (Published 20 August 2020) Cite this as: BMJ 2020;370:m3258

1. Fiona Godlee, editor in chief

Author affiliations

1. fgodlee@bmj.com
   Follow Fiona on Twitter @fgodlee

Few can doubt that we need a vaccine for covid-19 as soon as possible, and great strides are being made, including in our understanding of the immunology of SARS-CoV-2.1 But what damage may result from the race to create one? The World Health Organization has produced guidance on minimum characteristics for a vaccine, including 50% efficacy, temperature stability, potential for rapid scale-up, and proper evaluation against comparators. But, writes Els Torreele, these basic requirements are being rapidly eroded by the prevailing view that anything is better than nothing.2 So instead we are heading for vaccines that reduce severity of illness rather than protect against infection, provide only short lived immunity, and will at best have been trialled by the manufacturer against placebo. As well as damaging public confidence and wasting global resources by distributing a poorly effective vaccine, this could change what we understand a vaccine to be. Instead of long term, effective disease prevention it could become a suboptimal chronic treatment. This would be good for business but bad for global public health.

“Vaccine nationalism” is also a concern, says Daniel Altmann.3 Russia’s approval of its vaccine, based on a small unpublished phase 2 study in 38 volunteers, suggests we are already in the grip of a cold war style arms race, he says. Side stepping the need for a large phase 3 trial is like “entering a marathon, running the first few metres, then unilaterally crowning yourself the winner as all the others run ahead.”

Proper testing for patient safety is at the heart of a new drive for ergonomic design of medical equipment, writes Jane Feinman.4 Ergonomics, or human factors, means reducing the likelihood of human error, and is especially important for high risk equipment being used in stressful and unfamiliar situations such as those experienced by staff at the height of the pandemic. Perhaps covid-19 will inspire a widespread passion for good design, evaluation, and procurement, so that staff are no longer scapegoats for mistakes caused by poorly purchased equipment.

Are we in the UK ready for winter? John Middleton predicts a perfect storm of resurgent covid-19, flu, a backlog of untreated long term conditions, excess cold related mortality, and the effects of economic collapse and a possible no deal Brexit.5 To be ready, he concludes, we will need all the public health interventions that weren’t properly implemented from the start: surveillance, test and trace, physical distancing, quarantine and isolation, and protection of staff and vulnerable groups. Now is the time to prepare, but for this the UK needs a strategy rather than a continued round of knee jerk reactions to events.6

Posted by Meryl Nass, M.D. at 8:45 PM